Literature DB >> 23152706

The Danish national type 2 diabetes cohort - the DD2 study.

Henrik Toft Sørensen1, Søren Friborg, Jørgen Rungby, Jens Sandahl Christensen, Allan Vaag, Henning Beck-Nielsen.   

Abstract

Entities:  

Year:  2012        PMID: 23152706      PMCID: PMC3496314          DOI: 10.2147/CLEP.S31104

Source DB:  PubMed          Journal:  Clin Epidemiol        ISSN: 1179-1349            Impact factor:   4.790


× No keyword cloud information.

Editorial

Type 2 diabetes is a pandemic and an enormous public health problem. This supplemental issue of Clinical Epidemiology describes the rationale, design, and implementation of the establishment of a large cohort of all Danes with type 2 diabetes (the DD2 study) and of a biobank to bridge the scientific disciplines of epidemiology, clinical medicine, genetics, epigenetics, and pharmacology. This will most likely result in great benefits for the application of evidence-based medicine to the care of, and improved outcomes for, Danish type 2 diabetes patients. This real-life clinical scientific investment will be an international resource for diabetes research for many years to come. Type 2 diabetes is a rapidly growing disease affecting around 205 million people worldwide and, in a “worst case scenario”, 439 million will be diagnosed with type 2 diabetes by the year 2025.1 The disease is associated with a two-fold increased mortality rate compared with the general population, due to complications such as myocardial infarction, stroke, gangrene in the lower extremities, end-stage renal failure, and blindness. The excess global mortality in 2000 attributable to diabetes overall, most of which was attributable to type 2 diabetes, was 2.9 million deaths. These complications are very troublesome for the individual diabetic patient and major public health problem. Therefore, cost-effective national organization and intervention are strongly needed, both in order to prevent the disease, but also in an attempt to improve treatment of the metabolic abnormalities behind the disease with the aim of preventing the devastating complications. Recent clinical trials2,3 have emphasized the importance of early intensive treatment of type 2 diabetes patients in order to prevent complications and improve quality of life. Therefore, evidence for new national guidelines for treatment and organisation for newly diagnosed type 2 diabetes patients is needed. In this case – if the guidelines are effective – the prognosis of newly diagnosed patients may be expected to improve significantly. The overall aim of the DD2 study is to near-normalize metabolic control in newly diagnosed type 2 diabetes patients in order to prevent diabetic complications and improve quality of life. The DD2 study thus has two specific aims: To investigate whether or not it is possible through treatment guidelines and structured organization to near-normalize the risk profile and to avoid/reduce diabetic complications by continuous monitoring through Danish health registries, thereby obtaining knowledge about predictors for the long-term outcome and thus objectives for new interventions. To establish a biobank of DNA and plasma, urine, and tissue samples for individual characterization of type 2 diabetes patients that will improve the prognosis and build a platform for individualized treatment. In Denmark the outcome of treatment and clinical course can be followed through comprehensive health registries with complete follow-up.4 Therefore the DD2 study will be able to evaluate treatment and intervene if the current treatment fails. Based on the data obtained, outcome will be evaluated prospectively, independently of the specific phenotypes and genotypes, and will thus be unbiased. The identification of new genes and pathways involved in type 2 diabetes predisposition and increased risk of diabetic complications offers opportunities for developing novel therapeutic and preventative approaches. Furthermore, the identification of additional genetic variants – both protective and risk variants – may render it possible to use patterns of predisposition to tailor individual management of these conditions. Denmark holds an internationally leading position within many aspects of clinical care and diabetes research, but such Danish research has been carried out in many institutions focusing on different aspects such as physiology, clinical medicine, health services research, biotechnology, clinical epidemiology, and biostatistics. The pandemic of type 2 diabetes is showing no signs of abatement and therefore progress is urgently needed to slow progression and reduce the consequences. The establishment of a large cohort of all Danes with type 2 diabetes and of a biobank to bridge all scientific disciplines will be an important international resource for diabetes research for many years.
Table S1

Hospitals participating in DD2 (June 2012)

HospitalDepartmentResponsible consultant
Odense University HospitalDept of Endocrinology MHenning Beck-NielsenJan-Erik Henriksen
Fredericia HospitalDept of MedicineHans Gjessing
NBG—Aarhus University HospitalDept of Medicine and EndocrinologyJens Sandahl Christiansen
Svendborg HospitalOutpatient Dept of DiabeteKlaus Levin
THG—Aarhus University HospitalDept of Medicine and EndocrinologyJørgen Rungby
Regional Hospital ViborgOutpatient Dept of EndocrinologyTorben Østergaard
Hospital Unit NyborgOutpatient Dept of EndocrinologyKlaus Levin
Vejle HospitalOutpatient Dept of MedicineCramer Christensen
Herlev HospitalDept of Medicine and EndocrinologyHenrik Westergaard
Regional Hospital SilkeborgDept of MedicineKlaus W Hansen
Regional Hospital RandersClinic of Endocrinology C10Henning K Nielsen
Bispebjerg HospitalIC – ResearchHans Perrild
Aalborg HospitalEndocrinology Lab 2 Hospital WestHans-Henrik Lervang
Regional Hospital HorsensDept of MedicineLise-Lotte Fisker
Hillerød HospitalDept of Cardiology and Endocrinology H 0652Michael Røder
Steno Diabetes CenterSteno Diabetes CenterPeter Rossing
Hospital Himmerland FarsøDept of MedicineHenning S Rønne
Sønderborg HospitalOutpatient Dept of Diabetes (M43)Hans R Rasmussen
Regional Hospital HerningDept of MedicineNancy Kristensen
Table S2

Departments/outpatient clinics that have consented to participate in DD2, but have not yet referred any patients

HospitalDepartmentResponsible consultant
RigshospitaletClinic of Medicine and EndocrinologyAllan Vaag
Aabenraa HospitalDept of MedicineJolanta Topolska
Haderslev HospitalDept of MedicineJolanta Topolska
Esbjerg HospitalDept of MedicineJeppe Gram
Hospital VendsysselDept of MedicineKim Helg Christiansen
Slagelse HospitalDept of MedicineHenning Friis Juhl
Dronninglund HospitalCenter of Medicine Aalborg, DronninglundGrzegorz Jaroslaw Pacyk
Frederiksberg hospitalClinic of Cardiology and Endocrinology EAnne Elisabeth Jarløv
Køge HospitalDept of MedicineLeif Breum
Helsingør HospitalDept of MedicinePer Lund / Pernille Vedel
Table S3

General practitioners participating in DD2 (June 2012)

NameAddress
GlamsbjerglægerneStensgårdsvej 20, 5620 Glamsbjerg
Mogens Carl PetersenFynsvej 7, 6000 Kolding
Lægerne Nørre Voldgade 58Nørrevoldgade 58, 5800 Nyborg
Lægerne WillemoesvejWillemoesvej 31, 5700 Svendborg
J.Ravn and M.RichertVestergade 2, 6640 Lunderskov
JacobilægerneRingkøbingvej 38, 6800 Varde
Lægerne i OksbølTorvegade 17, 6840 Oksbøl
Lili Tronegård-M. and Michael SchmidtBirkevej 2, 5300 Kerteminde
Lægerne J B Winsløws VejJ.B. Winsløws Vej 9 A, 5000 Odense C
Lægehuset—Farum MidtpunktNygårdterrasserne 204, 3520 Farum
Lægekompagniskabet Venusvej 2Venusvej 2, 7000 Fredericia
Paul Jørgen Schultz ApsHovedgaden Vest 86, 6500 Vojens
Lægerne Danmarksgade 13Danmarksgade 13, 7000 Fredericia
HaarbylægerneMøllevej 2, 5683 Hårby
Lægerne i Nr. Lyndelse ApsCarl Nielsensvej 1, 5792 Årslev
Lægerne i ØstergadeØstergade 1, 2., 5750 Ringe
Larsen, Glenthøj and NielsenBirkevej 2, 5300 Kerteminde
Claus Olesen and Elin FranckNy Vestergade 1, 1., 6000 Kolding
Lægehuset HavnepladsenTorvegade 16 A, 6800 Varde
Lægeklinikken Østergade 10Østergade 10, St., 6500 Vojens
Lægerne i VindebyBregningevej 48, 5700 Svendborg
Bylægen Peer KirkebjergSkt. Anne Plads 2, 5000 Odense C
Lægehuset i RøddingLouisevej 13, 6630 Rødding
Peter LarsenSkt. Anne Plads 4, 1., 5000 Odense C
Lægerne i HarndrupSkovvej 2, 5463 Harndrup
Bente K. BertelsenTvedgade 21, 6760 Ribe
Lægehuset Aps.Mellemgade 19 A, 5600 Faaborg
Lone Manane and Bent StolbergMommarkvej 259, 6470 Sydals
Uwe Karstensen ApsLåningen 1, 6280 Højer
Bau-Madsen, Fricke and StavenuiterEgevænget 4, 5771 Stenstrup
Dorothee PaulVidågade 48, st. tv., 6270 Tønder
Lægerne i BjertGl. Bjært 26, 6091 Bjert
Peter G PetersenMurtfeldts Plads 5, 6800 Varde
Morten ToftagerBirkevej 2, 5300 Kerteminde
Lægerne Vissingsgade 21Vissingsgade 21, 7100 Vejle
Lægerne KongensgadeKongensgade 27, 4., 5000 Odense C
Kim RønhofSankt Nicolai Gade 6, st., 5700 Svendborg
Hanne ChristensenKongensgade 3, 6070 Christiansfeld
Lægehuset Nørre AabyÆblehaven 1, 5580 Nørre Aaby
Lægerne Englandsgade 8Englandsgade 8, 6700 Esbjerg
Marianne BovSkt. Anne Plads 2, 1., 5000 Odense C
Stig GerdesDanmarksgade 11, 1. tv., 7000 Fredericia
Carsten Winther JakobsenKongensgade 38, 2. th., 5000 Odense C
Bak og LarsenTeglgårdsparken 100, 1., 5500 Middelfart
Lægerne VestergadeVestergade 2D, 1., 6600 Vejen
Berkjær, IversenBønløkke, Ellegaard Ulsnæs 4, 6300 Gråsten
Søndersø LægehusVesterled 2, 5471 Søndersø
Annemette AlsKongevej 37, 6300 Gråsten
Lægerne JernbanegadeJernbanegade 4, 7000 Fredericia
Lægerne Syrenvej2 Syrenvej 2, 7080 Børkop
Sundhedscenter VejleNordås 17K, 7100 Vejle
Peter Mikael Klubien M DMadsensvej 9,1, 3450 Allerød
Lægeklinikken Danmarksgade22 Danmarksgade 22, 7500 Holstebro
  4 in total

1.  Epidemiology. When an entire country is a cohort.

Authors:  L Frank
Journal:  Science       Date:  2000-03-31       Impact factor: 47.728

Review 2.  Type 2 diabetes across generations: from pathophysiology to prevention and management.

Authors:  Christopher J Nolan; Peter Damm; Marc Prentki
Journal:  Lancet       Date:  2011-06-24       Impact factor: 79.321

3.  Effects of intensive glucose lowering in type 2 diabetes.

Authors:  Hertzel C Gerstein; Michael E Miller; Robert P Byington; David C Goff; J Thomas Bigger; John B Buse; William C Cushman; Saul Genuth; Faramarz Ismail-Beigi; Richard H Grimm; Jeffrey L Probstfield; Denise G Simons-Morton; William T Friedewald
Journal:  N Engl J Med       Date:  2008-06-06       Impact factor: 91.245

4.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

  4 in total
  3 in total

1.  Assessment of short and long-term outcomes of diabetes patient education using the health education impact questionnaire (HeiQ).

Authors:  Ditte Hjorth Laursen; Karl Bang Christensen; Ulla Christensen; Anne Frølich
Journal:  BMC Res Notes       Date:  2017-06-15

2.  Sequencing reveals protective and pathogenic effects on development of diabetes of rare GLIS3 variants.

Authors:  Jihua Sun; Christian Theil Have; Mette Hollensted; Niels Grarup; Allan Linneberg; Oluf Pedersen; Jens Steen Nielsen; Jørgen Rungby; Cramer Christensen; Ivan Brandslund; Karsten Kristiansen; Wang Jun; Torben Hansen; Anette P Gjesing
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

3.  Comparison of diabetic and idiopathic sensory polyneuropathies with respect to nerve fibre affection and risk factors.

Authors:  Mustapha Itani; Sif Gylfadottir; Thomas Krøigård; Laura Gaist; Jakob Vormstrup Holbech; Alexander Gramm Kristensen; Pall Karlsson; Sören Möller; Hatice Tankisi; David Gaist; Troels S Jensen; Nanna Brix Finnerup; Søren Hein Sindrup
Journal:  BMJ Neurol Open       Date:  2022-03-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.